Last reviewed · How we verify
sarilumab SAR153191 (REGN88)
At a glance
| Generic name | sarilumab SAR153191 (REGN88) |
|---|---|
| Also known as | Kevzara |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) (PHASE2)
- A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer (PHASE1, PHASE2)
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer (PHASE2)
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (PHASE1, PHASE2)
- Sarilumab COVID-19 (PHASE3)
- An Observational Study on Sarilumab-exposed Pregnancies
- An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) (PHASE2)
- Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sarilumab SAR153191 (REGN88) CI brief — competitive landscape report
- sarilumab SAR153191 (REGN88) updates RSS · CI watch RSS
- Sanofi portfolio CI